Science | ImagiRation

Science

The proof is in the data.

MITA is the first and only language therapy application supported by clinical data.

In a 3-year clinical trial of 6,454 children with autism, language score in children who engaged with MITA has increased to levels that were 120% higher than in children with similar initial evaluations. This difference was statistically significant (p<0.0001). The manuscript describing the study has been published in the journal Healthcare.

The FDA has granted MITA a breakthrough device designation (Q210093). We are working with the FDA to establish a pathway for MITA to become a reimbursable digital medicine.



The driving force behind ImagiRation puzzles is the Prefrontal Synthesis theory, developed by the company’s co-founder Dr. Vyshedskiy. If you’re interested in reading more about this theory and Dr. Vyshedskiy’s research, please read “The Evolution of Language.”

INDEPENDENT SCIENTIFIC RESEARCH